Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC

Encorafenib plus cetuximab with chemotherapy is being called the new first-line standard for BRAF V600E-mutant metastatic colorectal cancer following new trial results. Medscape Medical News

Read the full article on medscape.com